LATE-BREAKING ABSTRACT: Safety of salmeterol/fluticasone propionate (FSC) compared to fluticasone propionate (FP) in 4-17 yr olds with asthma
David Stempel (Bellevue, WA, United States of America), David Stempel, Stanley Szefler, Soren Pedersen, Robert Zeiger, Herman Mitchell, Andrew Liu, Ibrahim Raphiou, Kenneth Kral, Anne Yeakey, Kathleen Buaron, Barbara Prillaman, Laurie Lee, Suyong Yun Kirby, Steven Pascoe
Source: International Congress 2016 – Paediatric asthma: from amniotic fluid to dirty streets
Disease area: Airway diseases, Paediatric lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
David Stempel (Bellevue, WA, United States of America), David Stempel, Stanley Szefler, Soren Pedersen, Robert Zeiger, Herman Mitchell, Andrew Liu, Ibrahim Raphiou, Kenneth Kral, Anne Yeakey, Kathleen Buaron, Barbara Prillaman, Laurie Lee, Suyong Yun Kirby, Steven Pascoe. LATE-BREAKING ABSTRACT: Safety of salmeterol/fluticasone propionate (FSC) compared to fluticasone propionate (FP) in 4-17 yr olds with asthma. Eur Respir J 2016; 48: Suppl. 60, 4798
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Safety of Inhaled fluticasone propionate in children 2-4 years old Source: Eur Respir J 2003; 22: Suppl. 45, 133s Year: 2003
The combination salmeterol (S) + fluticasone propionate (F) in mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001
Comparison of salmeterol/fluticasone propionate (sal/fp) combination versus monotherapy with fluticasone propionate (fp) in patients with mild to moderate asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009
The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/ fluticasone propionate (SFC) is well tolerated in patients with COPD over three years Source: Eur Respir J 2006; 28: Suppl. 50, 34s Year: 2006
Control of airway inflammation is maintained in asthma patients following a 60% reduction in ICS dose with fluticasone propionate/salmeterol (FSC) compared with higher dose fluticasone propionate (FP) alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004
LATE-BREAKING ABSTRACT: TRILOGY: a phase III study to evaluate the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) in COPD patients Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
LATE-BREAKING ABSTRACT: TRINITY: A phase III study to compare the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) with tiotropium (Tio) and a free triple combination of BDP/FF (Foster®) + Tio in COPD patients Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016
Low dose inhaled fluticasone propionate compared with montelukast in children 6-12 years old Source: Eur Respir J 2003; 22: Suppl. 45, 535s Year: 2003
Efficacy of combination fluticasone furoate/vilanterol (FF/VI) and salmeterol/fluticasone propionate (SFC) over 12 weeks in patients with COPD Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Efficacy and safety of once-daily (OD) fluticasone furoate (FF) 50mcg over 24 weeks in adults and adolescents with persistent asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Comparison of fluticasone propionate + salmeterol (FP+S) and montelukast (MK) on bronchial reactivity (BR), pulmonary function (PF) and clinical outcome in children with mild asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Efficacy of fluticasone furoate (FF)/vilanterol (VI) or FF alone in asthma patients with differing eosinophil (eos) levels Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
12 weeks comparing salmeterol/fluticasone proprionate (SFC, 50/100 microg b.d. diskus) versus fluticasone proprionate (FP, 250 microg b.i. diskus) as first-line regular asthma treatment Source: Eur Respir J 2003; 22: Suppl. 45, 236s Year: 2003
"Stepping down" in mild-to-moderate asthmatic children, being well controlled while receiving low doses of inhaled corticosteroids (ICS): nedocromil sodium (NS) vs. fluticasone propionate (FP) 100 mcg/day given either twice Source: Eur Respir J 2006; 28: Suppl. 50, 713s Year: 2006
Seasonality of asthma exacerbations: efficacy of fluticasone furoate/vilanterol 100/25µg (FF/VI) vs fluticasone furoate 100µg (FF) alone Source: International Congress 2017 – Asthma management Year: 2017
LATE-BREAKING ABSTRACT: Long-term effects of combined extra-fine beclomethasone (BECL) and formoterol (FORM) treatment in asthma patients Source: Annual Congress 2009 - Cellular-tissue modifications and functional evaluation in COPD patients Year: 2009
Late Breaking Abstract - Dose responses for topical efficacy and systemic activity, dose equivalence and relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects. Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019
Variability in asthma and treatment efficacy as determined by weekly response rates with fluticasone propionate/salmeterol 100/50mcg (FSC) compared with montelukast 10mg (MON) Source: Eur Respir J 2003; 22: Suppl. 45, 259s Year: 2003
Effect of switching from high dose fluticasone propionate (FP) to FP/salmeterol (FSC) on airway inflammation in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 44s Year: 2004
Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010